Drugs / Vactosertib
Trials 21 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT05400122 | Sep 2022 → Dec 2026 | Hodgkins lymphoma, acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic myeloid leukemia +5 | David Wald | Suspended | No outcome recorded |
| Phase 1 | NCT04258072 | Apr 2021 → Dec 2022 | pancreatic ductal adenocarcinoma | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 1 | NCT03704675 | Aug → Sep 2018 | — | MedPacto, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03074006 | Jan 2018 → Dec 2019 | myelodysplastic syndrome | MedPacto, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03143985 | Jul 2017 → Feb 2022 | plasma cell myeloma | Koen van Besien | Completed | No outcome recorded |
| Phase 1 | NCT02160106 | Jul 2014 → Jul 2018 | — | MedPacto, Inc. | Completed | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT05588648 | May 2023 → Sep 2025 overdue | osteosarcoma | MedPacto, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03666832 | Jun 2019 → Dec 2022 | malignant pancreatic neoplasm | Joon Oh Park | Unknown | No outcome recorded |
| Phase 1/2 | NCT03802084 | Apr 2019 → Mar 2024 | desmoid tumor | Hyo Song Kim | Completed | No outcome recorded |
| Phase 1/2 | NCT03732274 | Feb 2019 → May 2024 | non-small cell lung carcinoma | MedPacto, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT03724851 | Dec 2018 → May 2024 | colorectal cancer, gastric cancer, gastroesophageal junction adenocarcinoma | MedPacto, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT03698825 | Aug 2018 → Jan 2022 | gastric cancer | MedPacto, Inc. | Completed | No outcome recorded |
| Phase 29 trials | ||||||
| Phase 2 | NCT06044311 | Sep 2024 → Dec 2026 | esophageal adenocarcinoma, gastroesophageal junction adenocarcinoma | Melissa Lumish | Suspended | No outcome recorded |
| Phase 2 | NCT05436990 | Feb 2023 → Mar 2025 | mucosal melanoma | Yonsei University | Terminated | No outcome recorded |
| Phase 2 | NCT04656002 | Oct 2022 → Dec 2023 | gastric adenocarcinoma | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT06219733 | Jun 2021 → May 2022 | dermoid cyst | MedPacto, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT04893252 | Jun 2021 → Dec 2023 | gastric neoplasm | Hark Kyun Kim | Unknown | No outcome recorded |
| Phase 2 | NCT04515979 | Dec 2020 → Aug 2024 | non-small cell lung carcinoma | MedPacto, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT04064190 | Dec 2019 → Dec 2023 | urothelial carcinoma | MedPacto, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT04103645 | Nov 2019 → Jul 2024 | myeloproliferative neoplasm | Weill Medical College of Cornell University | Terminated | No outcome recorded |
| Phase 2 | NCT03844750 | Jul 2019 → Sep 2025 | colorectal carcinoma, metastatic malignant neoplasm | Chloe Atreya, MD, PhD | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 22 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vactosertib | “Dose Escalation and Proof-of-Concept Studies of Vactosertib (TEW-7197) Monotherapy in Patients With MDS” NCT03074006 ↗ |
| Known as | Ew-7197 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3260567 ↗ |
| Known as | TEW-7197 | “TEW-7197 (vactosertib), a TGF-β inhibitor and imatinib demonstrated synergistic effect in vitro and xenograft model.” NCT03802084 ↗8“Dose Escalation and Proof-of-Concept Studies of Vactosertib (TEW-7197) Monotherapy in Patients With MDS” NCT03074006 ↗ “Vactosertib(TEW-7197)/ Durvalumab” NCT04064190 ↗ |
| Action | Inhibit | “inhibits protein serine/threonine kinase of activin receptor-like kinase 5 (ALK5)” NCT02160106 ↗ |
| Modality | Small molecule | “orally bioavailable small molecule” NCT02160106 ↗ |
| Route | Oral | “oral administration” NCT02160106 ↗ |
| Target | TGFBR1 | “Vactosertib is an inhibitor of protein serine/threonine kinase activity of TGF-β receptor type 1 (TGFBR1; ALK5).” NCT03143985 ↗ |